FAP and pancreatic ductal adenocarcinoma: A novel in vivo approach using mannose-modified mRNA lipid nanoparticles to target CD206 on M2 reprogrammed them into FAP-CAR-M, yielding decreases in activated cancer-associated fibroblast markers, collagen volume, and Col1a1 in a pancreatic ductal adenocarcinoma model (90).